Mechelen, Belgium; 21 May 2007 - Galapagos NV (Euronext & LSE: GLPG) announces that its service division BioFocus DPI has signed agreements with Cancer Research Technology Limited (CRT) and the University of Rochester Medical Center (URMC). Dr Katherine Hilyard has been appointed as Vice President, Biological Sciences for BioFocus DPI. Furthermore, Galapagos announces that it has recruited Clinquest for assisting the Company in preparation of its clinical trials for its bone & joint pipeline. Dr Cees Wortel from Clinquest will operate as Acting Chief Medical Officer for Galapagos.
